VXRT.OQXVaxart, INC

Form 4: Vaxart's Chief Medical Officer Reports Share Transactions

Sentiment:

SEC Form 4 Filing


James F. Cummings, Chief Medical Officer of Vaxart, Inc., reports the withholding of shares to cover tax obligations and shares acquired under the Employee Stock Purchase Plan.

Delay expectedThe transaction report was filed late due to administrative oversight.

Summary

  • James F. Cummings, the Chief Medical Officer of Vaxart, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
  • The report indicates that shares were withheld by the issuer to satisfy income tax obligations related to the vesting of Restricted Stock Units (RSUs) on March 28, 2023 (3,267 shares at $0.7502) and March 18, 2025 (6,772 shares at $0.5702).
  • Cummings also reported that he acquired 75,618 shares under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.
  • Following these transactions, Cummings beneficially owns 343,049 shares of Vaxart common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are related to standard compensation practices and tax obligations. The late filing is a minor negative.

Positives

  • Cummings' participation in the Employee Stock Purchase Plan indicates confidence in the company's future.

Negatives

  • The Form 4 filing was submitted late due to administrative oversight.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

  • Monitoring insider transactions is a common practice in the pharmaceutical industry to gauge management's sentiment and potential future performance.
  • Comparing the frequency and size of insider transactions at Vaxart to those of peers like Novavax (NVAX) or Moderna (MRNA) can provide insights into relative valuation and management confidence.

Stakeholder Impact

  • The transactions have a minimal direct impact on stakeholders, primarily providing transparency regarding insider ownership.

Key Dates

DateDescription
03/28/2023Shares withheld to satisfy income tax obligations in connection with the net settlement of RSUs vested.
03/18/2025Shares withheld to satisfy income tax obligations in connection with the net settlement of RSUs vested.
03/20/2025Date of signature for the report.

Keywords

Form 4, Vaxart, VXRT, James F. Cummings, Chief Medical Officer, Beneficial Ownership, Stock Transactions, Employee Stock Purchase Plan, Restricted Stock Units, Tax Withholding

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.